BCAL Diagnostics Ltd
ASX:BDX

Watchlist Manager
BCAL Diagnostics Ltd Logo
BCAL Diagnostics Ltd
ASX:BDX
Watchlist
Price: 0.125 AUD 4.17% Market Closed
Market Cap: AU$46m

Net Margin

-273.2%
Current
Declining
by 26%
vs 3-y average of -247.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-273.2%
=
Net Income
AU$-7.2m
/
Revenue
AU$2.7m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-273.2%
=
Net Income
AU$-7.2m
/
Revenue
AU$2.7m

Peer Comparison

Country Company Market Cap Net
Margin
AU
BCAL Diagnostics Ltd
ASX:BDX
45.7m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD
Loading...

Market Distribution

In line with most companies in Australia
Percentile
35th
Based on 4 004 companies
35th percentile
-273.2%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

BCAL Diagnostics Ltd
Glance View

Market Cap
46m AUD
Industry
Biotechnology

BCAL Diagnostics Ltd. develops screening tests for the early detection of breast cancer. The company is headquartered in Sydney, New South Wales. The company went IPO on 2021-07-21. The firm is developing a blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, accurate and available to all women regardless of age, race and geographic location. The company has developed a non-invasive blood test for the detection of breast cancer. The firm is developing an in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vehicles (EVs) from a patient's plasma or blood sample to diagnose the presence of cancer cells in a patient’s body. BCAL has partnered with integrated cancer care and cardiac provider GenesisCare to conduct clinical research required for regulatory approvals across jurisdictions.

BDX Intrinsic Value
0.367 AUD
Undervaluation 66%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-273.2%
=
Net Income
AU$-7.2m
/
Revenue
AU$2.7m
What is BCAL Diagnostics Ltd's current Net Margin?

The current Net Margin for BCAL Diagnostics Ltd is -273.2%, which is below its 3-year median of -247.2%.

How has Net Margin changed over time?

Over the last 3 years, BCAL Diagnostics Ltd’s Net Margin has increased from -483.6% to -273.2%. During this period, it reached a low of -483.6% on May 30, 2022 and a high of -136% on Dec 31, 2023.

Back to Top